Table 1 Baseline characteristics of the participants
Intervention group | Control group | ||
|---|---|---|---|
213 | 219 | ||
Age | median (IQR) | 85 (80-89.5) | 85 (80-90) |
range | 75 - 103 | 75 - 102 | |
Female gender | n (%) | 136 (63.8) | 135 (61.6) |
CFS | median (IQR) | 6 (5-6) | 5 (5-6) |
Home-dwellinga | n (%) | 194 (91.1) | 170 (88.1) |
Number of medicationsb | median (IQR) | 10 (7-14) | 10 (7-14) |
Cardiovascular disease | n (%) | 123 (57.7) | 131 (59.8) |
Cognitive disorder | n (%) | 82 (38.5) | 93 (42.5) |
Pulmonary disease | n (%) | 43 (20.2) | 46 (21.0) |
Malignancy | n (%) | 28 (13.1) | 26 (11.9) |
Diabetes | n (%) | 54 (25.4) | 50 (22.8) |
Stroke or TIA in history | n (%) | 36 (16.9) | 39 (17.8) |
ED chief complaint: trauma | n (%) | 41 (19.2) | 43 (19.6) |
ED chief complaint: acute condition nontrauma | n (%) | 166 (77.9) | 172 (78.5) |
ED admission for other or nonspecific cause | n (%) | 6 (2.8) | 4 (1.8) |
NEWS2c | median (IQR) | 1 (0-3) | 1 (0-4) |
EQ-5D-5L-indexd | mean (SD) | 0.557 (0.283) | 0.545 (0.264) |
EQ-5D-5L-VASe | mean (SD) | 45.4 (27.1) | 41.8 (27.0) |